沙库巴曲缬沙坦片对慢性心功能不全患者血浆NT-proBNP、cTnI表达及心功能的影响  

The effects of sacubitril-valsartan tablets on the expressions of NT-proBNP,cTnI and cardiac function in patients with chronic cardiac insuffciency

作　　者：王秋实 李晓冉 姚瑶[2] Qiu-Shi WANG;Xiao-Ran LI;Yao YAO(Department of Cardiology,Beijing Friendship Hospital,Capital Medical University,Beijing 100050,China;Department of Pathology,Peking University Third Hospital,Beijing 100191,China)

机构地区：[1]首都医科大学附属北京友谊医院心内科,北京100050 [2]北京大学第三医院病理科,北京100191

出　　处：《中国药师》2023年第11期298-303,共6页China Pharmacist

摘　　要：目的 观察沙库巴曲缬沙坦对慢性心功能不全患者氨基末端脑钠肽前体(NT-proBNP)、肌钙蛋白Ⅰ(cTnI)表达及心功能的影响。方法 选取2021年11月至2022年12月在首都医科大学附属北京友谊医院诊治的慢性心功能不全患者为研究对象,分为研究组(沙库巴曲缬沙坦片)和对照组(缬沙坦胶囊)。观察两组患者的总有效率、心功能指标[左心室射血分数(LVEF)、左心室收缩末期内径(LVESD)、左心室舒张末期内径(LEVDD)]、血浆NT-proBNP、cTnI、可溶性生长刺激表达基因2蛋白(sST2)、血管紧张素(AngⅡ)及不良反应发生率。结果研究共纳入100例心功能不全患者,研究组和对照组各50例。治疗后,研究组的总有效率高于对照组(P <0.05);研究组LVEF显著高于对照组,而LVESD、LEVDD显著低于对照组(P <0.05)。治疗后2组患者血浆NT-proBNP、cTnI、AngⅡ、sST2差异有统计学意义(P <0.05),治疗前后2组以上指标差异均有统计学意义(P <0.05)。两组不良反应的差异无统计学意义(P> 0.05)。结论 沙库巴曲缬沙坦片治疗慢性心功能不全患者,可改善患者心功能、预后、安全性较好。Objective To observe the effects of sacubitril-valsartan tablets on the expressions of N terminal pro B type natriuretic peptide(NT-proBNP),troponin I(cTnI) and cardiac function in patients with chronic cardiac insufficiency.Methods Patients with chronic cardiac insufficiency who were diagnosed and treated in Beijing Friendship Hospital of Capital Medical University from November 2021 to December 2022 were selected as the study subjects,and were divided into the study group(sacubitril-valsartan tablets) and the control group(valsartan capsules)according to the random number table method.The total effective rate,cardiac function indexes [le?t ventricular ejection fraction(LVEF),le?t ventricular end systolic diameter(LVESD),le?t ventricular end-diastolic diameter(LEVDD)],plasma NT-proBNP,cTnI,soluble growth stimulation expression gene 2 protein(sST2),angiotensin(AngII) and the incidence of adverse reactions were observed in the two groups.Results A total of 100 patients with cardiac insufficiency were included in the study,with 50 in the study group and 50 in the control group.A?ter treatment,the total effective rate of the study group was higher than that of the control group(P<0.05).The LVEF in the study group was significantly higher than that in the control group,while the LVESD,LEVDD were significantly lower than those in the control group(P<0.05).A?ter treatment,the plasma of NT-proBNP,cTnI,AngII,and sST2 in two groups had statistical difference(P<0.05) and the difference in the above indicators before and after treatment in two groups were statistically siginficant(P<0.05).The differences in adverse reactions between two groups were not statistically significant(P>0.05).Conclusion The treatment of chronic heart failure patients with sacubitril-valsartan tablets can improve heart function,prognosis,and safety.

关 键 词：沙库巴曲缬沙坦片 慢性心功能不全 氨基末端脑钠肽前体 肌钙蛋白Ⅰ 心功能 

分 类 号：R541.6[医药卫生—心血管疾病]